Skip to content
  • Sunday, June 1, 2025

New Economy World

The world economy is the economy of all humans in the world

Banner Add
  • Home
  • Blog
  • Finance News
  • Insurance
  • Investing
  • Construction
  • Property
  • Stock
  • Tech
  • Venture Capital
  • Home
  • Finance News
  • Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
Finance News

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

04/04/2025
admin

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

#Sangamo #Therapeutics #Scope #Eli #Lilly #Licensing #Deal

Tags: Deal, Eli, Licensing, Lilly, Sangamo, Scope, Therapeutics

Post navigation

OpenAI’s models ‘memorized’ copyrighted content, new study suggests
BODI stock touches 52-week low at $5.09 amid market challenges

Finance and Economics

Recent Posts

Stock

DATROWAY ® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

01/06/2025
admin
Finance News

Lakeland Financial Corporation: Upside Is Difficult To Justify (NASDAQ:LKFN)

01/06/2025
admin
Stock

US debt is 'sound', no concerns about US dollar's reserve role, Taiwan's central bank says

01/06/2025
admin
Finance News

Sentiment Sours On Canopy Growth As It Reports High Net Loss And Lower Revenues

01/06/2025
admin
Stock

Introducing Tempus One in the EHR with Integrated Guidelines

01/06/2025
admin
Finance News

Canadian Natural Resources: The Dividend Engine Hiding In Plain Sight

01/06/2025
admin
Stock

Ukraine's Zelenskiy says Ukraine will attend Istanbul talks on Monday

01/06/2025
admin

Recent Posts

Stock

DATROWAY ® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

01/06/2025
admin
Finance News

Lakeland Financial Corporation: Upside Is Difficult To Justify (NASDAQ:LKFN)

01/06/2025
admin

Recent Posts

Stock

DATROWAY ® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

01/06/2025
admin
Finance News

Lakeland Financial Corporation: Upside Is Difficult To Justify (NASDAQ:LKFN)

01/06/2025
admin

Recent Posts

Stock

DATROWAY ® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

01/06/2025
admin
Finance News

Lakeland Financial Corporation: Upside Is Difficult To Justify (NASDAQ:LKFN)

01/06/2025
admin
New Economy World News